PURPOSE: Functional analysis of the three recombinant human serum albumin (rHSA) domains and their potential as stand-alone proteins for use as drug delivery protein carriers. METHODS: Protein structure was examined by fluorescence and CD spectroscopy. Ligand binding was estimated by ultrafiltration. Antioxidant activity was estimated by measuring the quenching of dihydrorhodamine 123. Esterase-like activity and enolase-like activity were estimated from the rate of hydrolysis of p-nitrophenyl acetate and conversion of dihydrotestosterone from the 3-keto to 3-enol form, respectively. The domains of human serum albumin (HSA) were radiolabeled with 111In to evaluate their pharmacokinetics. RESULTS: The ligand binding ability of subsites Ia and Ib could not be detected in domain II. However, the binding of ligands to subsite Ic and site II were preserved in domain II and domain III, respectively. Domain III retained about 45% of its esterase-like activity, and weaker esterase-like activity was also observed in domain I. All domains showed low enolase-like activity in a pH 7.4 phosphate buffer, but domain II had higher activity in a pH 9.2 carbonate buffer. Domain I exhibited antioxidant activity comparable to that of rHSA. All three of the 111In-radiolabeled domains were rapidly eliminated from HSA, with high accumulation in the kidneys. CONCLUSION: Domain I of HSA has great potential for further development as a drug delivery protein carrier, due to its favorable properties and the presence of a free cysteine residue.
PURPOSE: Functional analysis of the three recombinant humanserum albumin (rHSA) domains and their potential as stand-alone proteins for use as drug delivery protein carriers. METHODS: Protein structure was examined by fluorescence and CD spectroscopy. Ligand binding was estimated by ultrafiltration. Antioxidant activity was estimated by measuring the quenching of dihydrorhodamine 123. Esterase-like activity and enolase-like activity were estimated from the rate of hydrolysis of p-nitrophenyl acetate and conversion of dihydrotestosterone from the 3-keto to 3-enol form, respectively. The domains of humanserum albumin (HSA) were radiolabeled with 111In to evaluate their pharmacokinetics. RESULTS: The ligand binding ability of subsites Ia and Ib could not be detected in domain II. However, the binding of ligands to subsite Ic and site II were preserved in domain II and domain III, respectively. Domain III retained about 45% of its esterase-like activity, and weaker esterase-like activity was also observed in domain I. All domains showed low enolase-like activity in a pH 7.4 phosphate buffer, but domain II had higher activity in a pH 9.2 carbonate buffer. Domain I exhibited antioxidant activity comparable to that of rHSA. All three of the 111In-radiolabeled domains were rapidly eliminated from HSA, with high accumulation in the kidneys. CONCLUSION: Domain I of HSA has great potential for further development as a drug delivery protein carrier, due to its favorable properties and the presence of a free cysteine residue.
Authors: L Beljaars; G Molema; B Weert; H Bonnema; P Olinga; G M Groothuis; D K Meijer; K Poelstra Journal: Hepatology Date: 1999-05 Impact factor: 17.425
Authors: Andreas Wunder; Ulf Müller-Ladner; Ernst H K Stelzer; Jürgen Funk; Elena Neumann; Gerd Stehle; Thomas Pap; Hannsjörg Sinn; Steffen Gay; Christoph Fiehn Journal: J Immunol Date: 2003-05-01 Impact factor: 5.422
Authors: P Yeh; D Landais; M Lemaître; I Maury; J Y Crenne; J Becquart; A Murry-Brelier; F Boucher; G Montay; R Fleer Journal: Proc Natl Acad Sci U S A Date: 1992-03-01 Impact factor: 11.205
Authors: T Kjeldsen; A F Pettersson; L Drube; P Kurtzhals; I Jonassen; S Havelund; P H Hansen; J Markussen Journal: Protein Expr Purif Date: 1998-07 Impact factor: 1.650
Authors: R T Jaspers; B J van Beek-Harmsen; M A Blankenstein; G Goldspink; P A Huijing; W J van der Laarse Journal: Pflugers Arch Date: 2008-05-21 Impact factor: 3.657
Authors: Abhilash Jayaraj; Heidi A Schwanz; Daniel J Spencer; Shalender Bhasin; James A Hamilton; B Jayaram; Anna L Goldman; Meenakshi Krishna; Maya Krishnan; Aashay Shah; Zhendong Jin; Eileen Krenzel; Sashi N Nair; Sid Ramesh; Wen Guo; Gerhard Wagner; Haribabu Arthanari; Liming Peng; Brian Lawney; Ravi Jasuja Journal: Endocrinology Date: 2021-02-01 Impact factor: 4.736
Authors: Anna L Goldman; Shalender Bhasin; Frederick C W Wu; Meenakshi Krishna; Alvin M Matsumoto; Ravi Jasuja Journal: Endocr Rev Date: 2017-08-01 Impact factor: 25.261